The primary purpose of this study is to demonstrate that the BD 4mm x 32G Ultra-Fine Nano pen
needle provides equivalent glycemic control to the BD 8mm x 31G Ultra-Fine short pen needle
as measured by fructosamine (FRU) among Lantus®, Levemir®, and/or NPH users taking one or
more single daily injections of greater than 40 units of insulin.
Glycemic control, injection pain, leakage, preference, comfort, and other parameters will be
compared between the 4mm x 32G and the 8 mm x 31 G pen needle after three weeks of use of
each device. Sufficient numbers of subjects taking Lantus® as their basal insulin will be
enrolled so as to allow for pre-specified analysis of this subgroup.